Goldie–Coldman and bevacizumab beyond disease progression
BJ Giantonio - Nature reviews Clinical oncology, 2009 - nature.com
Nature reviews Clinical oncology, 2009•nature.com
Targeted therapies offer new hope in overcoming the challenges encountered with
conventional chemotherapy. However, little is known about the precise mechanisms that
cause resistance. These issues are discussed in light of data from the BRiTE study, which
indicate that the antiangiogenic effects of bevacizumab might persist despite the
development of resistance to first-line chemotherapy.
conventional chemotherapy. However, little is known about the precise mechanisms that
cause resistance. These issues are discussed in light of data from the BRiTE study, which
indicate that the antiangiogenic effects of bevacizumab might persist despite the
development of resistance to first-line chemotherapy.
Targeted therapies offer new hope in overcoming the challenges encountered with conventional chemotherapy. However, little is known about the precise mechanisms that cause resistance. These issues are discussed in light of data from the BRiTE study, which indicate that the antiangiogenic effects of bevacizumab might persist despite the development of resistance to first-line chemotherapy.
nature.com
